A single - center, retrospective observational study comparing the efficacy of empagliflozin and dapagliflozin as add-on therapy in type 2 diabetic patients
Year: 2024
Type: article
Study design: Observational Study
Abstract: Objective: This study aimed to compare the efficacy of dapagliflozin and empagliflozin as add-on therapies for type 2 diabetes mellitus (T2DM) over 6 months in a real-world setting, focusing on key metabolic parameters.Methods: We conducted a single-center, retrospective observational study involving 74 T2DM patients receiving either dapagliflozin (10mg) or empagliflozin (25mg) as add-on therapy. Data from 843 patients’s electronic medical records were collected at the Center for Endocrinology and Diabetes, Da Nang Family Hospital, between May 2021 and June 2023. Baseline data and data from the 3rd and 6th months of treatment were analyzed using SPSS software (version 20.0). Statistical significance was set at p < 0.05.Results: The mean participant age was 58.8 years, with 54.1% females. Mean baseline HbA1c and fasting blood glucose were 8.18% and 9.1 mmol/L, respectively. After 6 months of SGLT2i treatment, both medications significantly improved glycemic control: HbA1c decreased from 8.18% to 7.3% (p < 0.05), and fasting plasma glucose dropped from 9.1 mmol/L to 7.4 mmol/L (p < 0.05). Systolic blood pressure also decreased significantly, from 130.7 mmHg to 126.5 mmHg (p < 0.05). Although a trend towards weight reduction (1.5 kg) was observed, it was not statistically significant (p > 0.05). Notably, empagliflozin led to a significantly greater decrease in fasting plasma glucose compared to dapagliflozin (p < 0.05). No other significant differences in metabolic parameters were observed between the groups at either 3 or 6 months. Conclusion: Both dapagliflozin and empagliflozin demonstrated significant efficacy as add-on therapies forT2DM patients, improving glycemic control, reducing blood pressure, and potentially promoting weight loss. While empagliflozin showed slightly better BMI, body weight and fasting plasma glucose reduction after 3 months, further research is needed to confirm this finding and explore underlying mechanisms.
Authors: Nguyen Van Vy Hau, Nguyen Van Bang, Nguyen Thi Xuan, Pham Nguyen Tuyen Linh, Nguyen Thi Ngoc Thoi, Vo Thanh Trang, Phan Minh Trung, Le Van Chi, Nguyen Hai Thuy
Institution: Colorado Springs School District 11
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W4402941593